Compare Pfizer Inc (PFE) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs DENTSPLY SIRONA Inc — how do they compare? Pfizer Inc trades at $27.83 (market cap $158.56B), while DENTSPLY SIRONA Inc trades at $8.67 (market cap $1.73B). The key difference: Pfizer Inc is far larger — about 91.7× DENTSPLY SIRONA Inc's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and DENTSPLY SIRONA Inc for 72 Days on average.
| PFE | XRAY | |
|---|---|---|
Market Cap | $158.56B | $1.73B |
Volume | 44,138,282 | 6,198,582 |
Sector | Health | Health |
52-Week High | $29.02 | $14.68 |
52-Week Low | $23.67 | $8.52 |
Typical Hold Time | 158 Days | 72 Days |
Enterprise Value | $210.06B | $3.80B |
Dividend Yield | 6.18% | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
DENTSPLY SIRONA (XRAY) trades at $8.54, near a 52-week low, with a bearish technical signal from moving averages. The company reported a Q2 2026 earnings beat but faces declining revenues and negative net income margins. Recent news highlights institutional stake increases and ongoing turnaround efforts amid sales weakness in dental segments.
The outlook remains challenging due to persistent profitability issues and high debt, though analyst consensus suggests upside to a $13.40 price target. Key risks include margin pressure and competitive threats, while potential catalysts include successful restructuring and digital dentistry growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
